Cancer immunotherapy such as immune checkpoint inhibitors (ICI) targeting programmed cell death‐1 (PD‐1), programmed cell death‐ligand 1 (PD‐L1) and cytotoxic T lymphocyte‐associated protein‐4, is widely used to treat various malignancies, including non‐small cell lung cancer (NSCLC); it has changed therapeutic approaches to malignancies. Here, CD274 is linked to lung cancer.